IL133585A0 - Soluble prodrugs of paclitaxel - Google Patents

Soluble prodrugs of paclitaxel

Info

Publication number
IL133585A0
IL133585A0 IL13358597A IL13358597A IL133585A0 IL 133585 A0 IL133585 A0 IL 133585A0 IL 13358597 A IL13358597 A IL 13358597A IL 13358597 A IL13358597 A IL 13358597A IL 133585 A0 IL133585 A0 IL 133585A0
Authority
IL
Israel
Prior art keywords
paclitaxel
onium salts
methods
novel
salts
Prior art date
Application number
IL13358597A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of IL133585A0 publication Critical patent/IL133585A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
IL13358597A 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel IL133585A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/010746 WO1998058927A1 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Publications (1)

Publication Number Publication Date
IL133585A0 true IL133585A0 (en) 2001-04-30

Family

ID=22261122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13358597A IL133585A0 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Country Status (10)

Country Link
EP (1) EP1001769B1 (sk)
JP (1) JP2002505682A (sk)
AT (1) ATE219363T1 (sk)
AU (1) AU3574097A (sk)
CA (1) CA2294606A1 (sk)
DE (1) DE69713526D1 (sk)
HU (1) HUP0002521A3 (sk)
IL (1) IL133585A0 (sk)
SK (1) SK182599A3 (sk)
WO (1) WO1998058927A1 (sk)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
EP1365759A2 (en) * 2001-01-18 2003-12-03 PHARMACIA & UPJOHN COMPANY Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
EP2390262A1 (en) 2003-05-16 2011-11-30 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
JP5523313B2 (ja) 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
PL2956175T3 (pl) 2013-02-15 2018-05-30 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3107899B1 (en) 2014-02-19 2020-08-12 Aviv Therapeutics, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
EP3463308B1 (en) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
AU2018211081A1 (en) 2017-01-18 2019-07-18 Bioatla, Inc. Chimeric antigen receptors against Axl or Ror2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CA3090129A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
US11660266B2 (en) 2018-04-11 2023-05-30 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
EP3823674A4 (en) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF
CN113692413A (zh) 2019-04-02 2021-11-23 肯乔克蒂生物技术股份有限公司 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法
JP2023512196A (ja) 2020-01-29 2023-03-24 ケンジョッケティ バイオテクノロジー，インク． 抗ｍｄｒ１抗体およびその使用
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
AU2021283080A1 (en) 2020-06-04 2022-12-15 Kenjockety Biotechnology, Inc. ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CN116490522A (zh) 2020-09-02 2023-07-25 肯乔克蒂生物技术股份有限公司 抗abcc1抗体及其应用
AU2021380659A1 (en) 2020-11-13 2023-06-01 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015571A1 (en) * 1995-10-27 1997-05-01 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
JP2002500667A (ja) * 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物

Also Published As

Publication number Publication date
JP2002505682A (ja) 2002-02-19
SK182599A3 (en) 2000-07-11
EP1001769B1 (en) 2002-06-19
HUP0002521A2 (hu) 2001-06-28
HUP0002521A3 (en) 2002-04-29
AU3574097A (en) 1999-01-04
EP1001769A1 (en) 2000-05-24
WO1998058927A1 (en) 1998-12-30
CA2294606A1 (en) 1998-12-30
EP1001769A4 (en) 2000-05-24
ATE219363T1 (de) 2002-07-15
DE69713526D1 (de) 2002-07-25

Similar Documents

Publication Publication Date Title
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUT68498A (en) L-dopa ester compositions and process to prepare them
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
RU94045155A (ru) Способы ингибирования болезни альцгеймера
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
MY125821A (en) Pharmaceutical composition of topiramate
AU9189301A (en) Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments
DK0975595T3 (da) Kokainanaloger
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
EP1024802A4 (en) (3SI (R), 4SI (R)) - SG (D) -TETRAHYDROCANNABINOLIC ACID AS AN INFLAMMATORY INHIBITOR AND ANALGESICA
PL342614A1 (en) Anticarcinogenic drugs
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
BG104983A (en) Aryl fused azapolycyclic compounds
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
MY126998A (en) Substituted pyrroles.
BR9714774A (pt) Pró-drogas solúveis de paclitaxel
JO2360B1 (en) Substituted pyrolates